A 63.5% PASI 100 rate at 16 weeks is not what the IL-23 class typically delivers at that timepoint — most approved competitors land in the 40–50% range by midpoint readouts — and that number, drawn from 63 participants in EVERLAST-A, is the clinical argument Oruka is building its entire regulatory strategy around. The result matters not just as an efficacy signal but as a dosing story: single 600 mg administrations of ORKA-001 kept drug concentrations above effective trough for a full year in Phase 1 PK data, with sustained IL-23 pathway suppression throughout. Annual dosing with PASI 100 rates at that level reframes what chronic psoriasis management could look like — not incremental improvement over risankizumab or guselkumab, but a categorical shift in treatment burden.
The Week 16 data is only the opening frame. What actually determines ORKA-001’s trajectory is the Week 28 readout and the 52-week follow-up subset, both expected in the second half of 2026. Those numbers will test whether the early efficacy holds under real durability pressure — whether a drug dosed once sustains PASI 100 through the back half of the year when trough levels, while above effective thresholds in PK models, face the heterogeneity of real patient pharmacology. EVERLAST-B, the Phase 2b trial now enrolling across North American and European sites, is designed so that Week 16 data supports Phase 3 initiation, meaning the design is already anticipating regulatory sequencing, not waiting on it.
ORKA-002 adds a second vector. Its half-life of 75–80 days supports twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa — a mechanistically distinct molecule targeting IL-17A/F that enters Phase 2 via ORCA-SURGE with data in 2027. HS is chronically underserved and notoriously difficult to treat; quarterly dosing with an extended half-life IL-17 inhibitor, if ORCA-SPLASH data holds, represents a serious competitive position against bimekizumab and secukinumab in that indication. Layering Halozyme’s Hypercon subcutaneous delivery technology onto ORKA-001 signals Oruka is already engineering the commercial presentation, not just the molecule.
The single number to track is Week 28 PASI 100 durability from EVERLAST-A. If complete clearance rates hold above 55% at that timepoint without meaningful erosion, Oruka’s Phase 3 design and BLA timeline become effectively locked — and the $700 million raise looks precisely sized rather than speculative.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
